Pioneering cellular medicines for women’s health
We’re developing off-the-shelf cell therapies for high-impact women’s diseases, with lead programs in ovarian cancer and endometriosis.
Pioneering excellence in the field of immunotherapy
Cartherics creates precisely-defined immunotherapy treatments to combat a variety of cancers, endometriosis and Alzheimer’s disease. We combine the best components of immune targeting utilising gene editing and CAR technology to advance cell therapy to provide more diverse off-the-shelf treatments for patients. Our team has strong backgrounds in research, development, and product commercialisation. And we partner with leading commercial and academic groups with complementary technology to push the boundaries of cell therapy for cancer and beyond.
Some of our partners
Latest news
Message from the CEO – December 2022
By Christine Filippis / December 14, 2022
This year has been an exciting and productive one for Cartherics. We opened our new and impressive research and development...
Read More
Breaking the Mould: Building a Research-Based Biotech Company in Australia from Scratch
By Christine Filippis / December 7, 2022
Ian Nisbet and Alan Trounson, AO Australia is a very challenging environment for early-stage biotechnology companies. Risk capital is hard...
Read More
Peter MacCallum Cancer Centre and Cartherics Announce Collaboration to Develop Autologous CAR-T Cell Therapy for Cutaneous T-Cell Lymphoma
By Christine Filippis / November 8, 2022
Melbourne, Victoria, Australia - 08 November 2022 The Peter MacCallum Cancer Centre (“Peter Mac”) and Cartherics Pty Ltd (“Cartherics”) announced...
Read More
